Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18919654 | 1.00 | KDM4E (0.45) | KDM4EALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL28572066 | 0.85 | USP30 (0.50) | ALDH1A1MAPK1RAB9AL3MBTL1 | |
| SCHEMBL28572069 | 0.85 | USP30 (0.50) | ALDH1A1MAPK1RAB9AL3MBTL1 | |
| SCHEMBL17803369 | 0.84 | MEN1 (0.49) | KDM4EALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL18919702 | 0.84 | ALDH1A1 (0.63) | KDM4EALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL18919704 | 0.84 | ALDH1A1 (0.63) | KDM4EALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL21874640 | 0.82 | GRM2 (0.40) | KMT2ABCHEACHEBACE1GRM2 | |
| SCHEMBL21874641 | 0.82 | GRM2 (0.40) | KMT2ABCHEACHEBACE1GRM2 | |
| SCHEMBL29253804 | 0.81 | HCAR3 (0.52) | KDM4EALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL25337223 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| CN-108290861-B | 1-cyano-pyrrolidine derivatives as USP30 inhibitors | 特殊治疗有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20200262838-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| EP-3383859-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-04-29 | — | — | EP | disclosed |
| EP-3383859-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. | Mission Therapeutics Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093718-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091488-B2 | 1-cyano-pyrrolidine derivatives as inhibitors of USP30 | USP30, USP1, USP20 | KDM4E 508/4885ALDH1A1 787/4885MEN1 3103/4885 |
| US-20200262838-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 | USP30, USP1, USP20 | KDM4E 508/4885ALDH1A1 787/4885MEN1 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.